These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 32104061)

  • 1. A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain.
    Überall MA
    J Pain Res; 2020; 13():399-410. PubMed ID: 32104061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry.
    Ueberall MA; Essner U; Mueller-Schwefe GH
    J Pain Res; 2019; 12():1577-1604. PubMed ID: 31190969
    [No Abstract]   [Full Text] [Related]  

  • 4. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
    J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry.
    Ueberall MA; Essner U; Vila Silván C; Mueller-Schwefe GHH
    J Pain Res; 2022; 15():267-286. PubMed ID: 35140513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis.
    Rabgay K; Waranuch N; Chaiyakunapruk N; Sawangjit R; Ingkaninan K; Dilokthornsakul P
    J Am Pharm Assoc (2003); 2020; 60(1):225-234.e6. PubMed ID: 31495691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective review of medical cannabis in cancer pain management.
    Blake A; Wan BA; Malek L; DeAngelis C; Diaz P; Lao N; Chow E; O'Hearn S
    Ann Palliat Med; 2017 Dec; 6(Suppl 2):S215-S222. PubMed ID: 28866904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.
    Motaghi E; Ghasemi-Pirbaluti M; Rashidi M; Alasvand M; Di Ciano P; Bozorgi H
    Eur J Clin Pharmacol; 2023 Mar; 79(3):371-381. PubMed ID: 36700997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials.
    Häuser W; Welsch P; Klose P; Radbruch L; Fitzcharles MA
    Schmerz; 2019 Oct; 33(5):424-436. PubMed ID: 31073761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research.
    Schoedel KA; Harrison SJ
    Curr Pharm Des; 2012; 18(32):5008-14. PubMed ID: 22716155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
    Prieto González JM; Vila Silván C
    Expert Rev Neurother; 2021 May; 21(5):547-558. PubMed ID: 33749480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.
    Zettl UK; Rommer P; Hipp P; Patejdl R
    Ther Adv Neurol Disord; 2016 Jan; 9(1):9-30. PubMed ID: 26788128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
    Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM
    Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.